Spots Global Cancer Trial Database for ovarian serous tumor
Every month we try and update this database with for ovarian serous tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02446600 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... | Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer | NCT02520115 | Adnexal Mass Borderline Ovar... Ovarian Clear C... Ovarian Endomet... Ovarian Neoplas... Ovarian Serous ... Recurrent Ovari... | Dexamethasone Laboratory Biom... Valproic Acid | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT02595892 | Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Berzosertib Gemcitabine Gemcitabine Hyd... | 18 Years - | National Cancer Institute (NCI) | |
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT02595892 | Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Berzosertib Gemcitabine Gemcitabine Hyd... | 18 Years - | National Cancer Institute (NCI) | |
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer | NCT03456700 | Ovarian Serous ... Recurrent Ovari... | Auranofin Laboratory Biom... Sirolimus | 18 Years - | Mayo Clinic |